Literature DB >> 35668307

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial).

Martha E Teke1, Areeba Saif1, Carrie E Ryan1, Stephanie C Lux1, Jonathan M Hernandez2, Kim A Reiss3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35668307     DOI: 10.1245/s10434-022-11917-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


× No keyword cloud information.
  6 in total

1.  Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Margaret A Tempero; Mokenge P Malafa; Mahmoud Al-Hawary; Stephen W Behrman; Al B Benson; Dana B Cardin; E Gabriela Chiorean; Vincent Chung; Brian Czito; Marco Del Chiaro; Mary Dillhoff; Timothy R Donahue; Efrat Dotan; Cristina R Ferrone; Christos Fountzilas; Jeffrey Hardacre; William G Hawkins; Kelsey Klute; Andrew H Ko; John W Kunstman; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Amol K Narang; Jorge Obando; Patricio M Polanco; Sushanth Reddy; Marsha Reyngold; Courtney Scaife; Jeanne Shen; Charles Vollmer; Robert A Wolff; Brian M Wolpin; Beth Lynn; Giby V George
Journal:  J Natl Compr Canc Netw       Date:  2021-04-01       Impact factor: 11.908

Review 2.  PARP Inhibitors in Pancreatic Cancer.

Authors:  Timothy J Brown; Kim A Reiss
Journal:  Cancer J       Date:  2021 Nov-Dec 01       Impact factor: 3.360

3.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Authors:  Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

4.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Authors:  Talia Golan; Pascal Hammel; Michele Reni; Eric Van Cutsem; Teresa Macarulla; Michael J Hall; Joon-Oh Park; Daniel Hochhauser; Dirk Arnold; Do-Youn Oh; Anke Reinacher-Schick; Giampaolo Tortora; Hana Algül; Eileen M O'Reilly; David McGuinness; Karen Y Cui; Katia Schlienger; Gershon Y Locker; Hedy L Kindler
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

5.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

Authors:  Andrew N J Tutt; Judy E Garber; Bella Kaufman; Giuseppe Viale; Debora Fumagalli; Priya Rastogi; Richard D Gelber; Evandro de Azambuja; Anitra Fielding; Judith Balmaña; Susan M Domchek; Karen A Gelmon; Simon J Hollingsworth; Larissa A Korde; Barbro Linderholm; Hanna Bandos; Elżbieta Senkus; Jennifer M Suga; Zhimin Shao; Andrew W Pippas; Zbigniew Nowecki; Tomasz Huzarski; Patricia A Ganz; Peter C Lucas; Nigel Baker; Sibylle Loibl; Robin McConnell; Martine Piccart; Rita Schmutzler; Guenther G Steger; Joseph P Costantino; Amal Arahmani; Norman Wolmark; Eleanor McFadden; Vassiliki Karantza; Sunil R Lakhani; Greg Yothers; Christine Campbell; Charles E Geyer
Journal:  N Engl J Med       Date:  2021-06-03       Impact factor: 176.079

6.  Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.

Authors:  Max M Wattenberg; Daniella Asch; Shun Yu; Peter J O'Dwyer; Susan M Domchek; Katherine L Nathanson; Mark A Rosen; Gregory L Beatty; Evan S Siegelman; Kim A Reiss
Journal:  Br J Cancer       Date:  2019-12-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.